imneskibart (AU-007)
Unresectable locally advanced or metastatic solid tumors (initial focus on melanoma, non-small cell lung cancer, renal cell carcinoma)
Phase 2Active
Key Facts
Indication
Unresectable locally advanced or metastatic solid tumors (initial focus on melanoma, non-small cell lung cancer, renal cell carcinoma)
Phase
Phase 2
Status
Active
Company
About Aulos Bioscience
Aulos Bioscience is a private, pre-revenue biotech leveraging an artificial intelligence-driven antibody discovery platform from its partner Biolojic Design to create novel IL-2 therapeutics. The company's lead asset, imneskibart, is in Phase 2 development for solid tumors, with initial data showing clinical activity in melanoma and non-small cell lung cancer. Aulos aims to overcome the historical limitations of IL-2 by precisely directing its immune-activating power, positioning itself in the competitive but high-potential cytokine therapeutics space for oncology.
View full company profile